Joinn Laboratories (China) (HKG:6127) said it expects its 2025 attributable profit to more than triple year on year, according to a Hong Kong bourse filing Tuesday.
Shares of the drug research company gained nearly 1% in late morning trade Wednesday.
The firm expects 232.6 million yuan to 348.9 million yuan in 2025 profit, up 214% to 371% when compared to 2024.
Revenue for the year is expected to decrease 14% to 22% year-on-year to 1.57 billion yuan to 1.74 billion yuan.
The firm expects to report its results by the end of March.